Adapted from Catley et al, Pharm Therap 2011

Slides:

Advertisements

Similar presentations

ARIA QUIDELINES ON MANAGEMENT OF ALLERGIC RHINITIS

Advertisements

Allergens (+ T H2 adjuvants?) T H2 dominancy Allergen exposure with microbial components Early in life Later in life T H1 dominancy Cross inhibition Atopy.

Hypereosinophilic Syndromes.  Produced in the bone marrow  Function to combat parasitic infections, ectoparasites, certain viral infections, and amplify.

Immunology of Asthma through Biologics Private Practice & St Michael’s Hospital Lecturer, Division of Clinical Immunology & Allergy Department of Medicine,

Prof. Dr. U. Wahn Long term use of omalizumab – Is the IgE response modified? Ulrich Wahn Department of Pediatric Pneumology and Immunology.

ALLERGIC REACTIONS Localized Anaphylaxis. ATOPIC DISEASES Localized anaphylaxis (common allergy) ~20% of US population Limited production of IgE and sensitization.

Upper Airways Research Laboratory Department of Otorhinolaryngology Advanced treatments of nasal polyposis: Anti-IL-5 and Anti-IgE Which for whom? Prof.

Downloaded from – Use of Montelukast for the Treatment of Seasonal (Spring) Allergic Rhinitis.

A woman with multiple mononeuropathies and eosinophilia Teaching NeuroImages Neurology Resident and Fellow Section © 2014 American Academy of Neurology.

Interactions between viral infections and allergy in exacerbating asthma.

Immune responses that are inadequately controlled, inappropriately targeted to host tissues, or triggered by commensal microorganisms or usually harmless.

AdvanSure ® for diagnosis of specific IgE Park, Jung-Won Allergy-Asthma Clinic, Severance Hospital.

Fig. 1. Algorithm for diagnosis and treatment of hypereosinophilia

Recent Developments in Allergy Diagnosis and Treatment

Moderate-to-Severe Asthma Management

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a.

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Ηωσινοφιλική κοκκιωμάτωση με πολυαγγειίτιδα – Νέες θεραπευτικές επιλογές Σακελλαρίου Γρηγόριος Αναπλ. Δντης Ρευματολογικού Τμήματος 424 ΓΣΝΕ.

HTRF® cytokine assays.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Alalia Berry, MD, William W. Busse, MD

Eosinophilic Esophagitis: Is It All Allergies?

Anti-IgE treatment of eosinophil-associated gastrointestinal disorders

Severe Asthma in Primary Care: Identification and Management

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

Diagnosis and management of anaphylaxis in precision medicine

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Peter J. Barnes, FMedSci, FRS

Jennifer L. Ingram, PhD, Monica Kraft, MD

A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthma William W. Busse, MD, Johannes Ring, MD, PhD, Johannes.

R. Balfour Sartor, MD Clinical Gastroenterology and Hepatology

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Advances in Severe Asthma Management

Challenges in Severe Asthma

SpA-SEA-D227A-induced CTL lyse MAb-coated EC

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

蔡易錚 MD. PhD. 新光醫院耳鼻喉科輔仁大學醫學系

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management

Current and Future Treatment of Peanut Allergy

Biologics and biomarkers for asthma, urticaria, and nasal polyposis

Airway inflammation in asthma and its consequences: Implications for treatment in children and adults Ratko Djukanovic, MD Journal of Allergy and Clinical.

Rhinophototherapy: A new therapeutic tool for the management of allergic rhinitis Andrea I. Koreck, MD, PhD, Zsanett Csoma, MD, Laszlo Bodai, Ferenc Ignacz,

Profiles of anti-inflammatory cytokines after endotoxin injection.

Novel targeted therapies for eosinophilic disorders

Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy.

Pathophysiologic Targets of Allergic Asthma

Mark J. Koury, MD, John H. Newman, MD, John J. Murray, MD

Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5− TH2 responses Calman Prussin, MD, Joohee Lee,

Claus Bachert, MD, PhD, Luo Zhang, MD, Phillippe Gevaert, MD

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Damal Kandadai Sriram, Govindaraj Gowri, Melvin George

Relationships between H. pylori, inflammation, and acid secretion.

Molecular and cellular mechanisms of allergic disease

Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700 Yae-Jean.

Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases Susan Lee, MD, Mark Ballow, MD Journal of.

Eosinophilic gastrointestinal disorders (EGID)

Dilution of anti-C6 monoclonal antibody shows the broader linear range of the Multiplex assay in comparison to standard ELISA. Shown is the dilution of.

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Schematic diagram of the potential cellular effects of interleukin (IL)-4/IL-13 on inflammatory and structural cells in asthma. Schematic diagram of the.

Foundations of Asthma.

Therapeutic administration of an anti-podoplanin antibody (α-PDPN) is beneficial during a mouse model of acute respiratory distress syndrome. Therapeutic.

Presentation transcript:

Adapted from Catley et al, Pharm Therap 2011 Anti-IL-5 Anti-IL-13 Anti-IL-4 Anti-TNF A number of monoclonal antibodies have been used in animal models and human eosinophilic disorders to target eosinophilic inflammation including anti-IL-5 (asthma, eosinophilic esophagitis, hypereosinophilic syndrome, nasal polyposis), anti-IL-13 (eosinophilic esophagitis, asthma), anti-TNF-alpha (asthma, eosinophilic esophagitis), anti-siglec-F (eosinophilia, eosinophilic esophagitis, eosinophilic gastroenteritis), and anti-IgE (asthma, eosinophilic esophagitis) Anti-IgE Anti-Siglec-F Adapted from Catley et al, Pharm Therap 2011

Selected Reviews List Catley et al, Monoclonal antibodies for the treatment of asthma, Pharmacology & Therapeutics 2011 Busse et al, A review of treatment with mepolizumab, an anti-IL-5 mAb in hypereosinophilic syndromes and asthma, JACI 2011 Stone and Prussin. Immunomodulatory therpy oeosinophili assoicate gastrointestinal diseases. Clin Exp Allergy, 2008